EORTC’s presence at ESMO 2024
10 Sep 2024
EORTC’s presence at this year’s ESMO Congress 2024, taking place from 13 to 17 September in Barcelona, is particularly noteworthy. We will be presenting seven abstracts, three of which are proffered papers to be delivered as oral presentations, alongside four poster displays. One of the proffered papers will be presented during the prestigious Presidential Symposium. Additionally, we will participate in four educational sessions, one of which is specifically designed for young oncologists.
Further details can be found in the table below.
EORTC ABSTRACTS |
|
| A RANDOMIZED MULTICENTER OPEN LABEL PHASE III TRIAL COMPARING ENZALUTAMIDE VS A COMBINATION OF RADIUM-223 (RA223) AND ENZALUTAMIDE IN ASYMPTOMATIC OR MILDLY SYMPTOMATIC PATIENTS WITH BONE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): FIRST RESULTS OF EORTC-GUCG 1333/PEACE-3
Silke Gillessen, Switzerland |
PRESIDENTIAL SYMPOSIUM I: PRACTICE CHANGING TRIALS Saturday, 14 September 16:30 - 16:42 Type: Proffered paper session Room: Barcelona Auditorium - Hall 2 Abstract number: LBA1 |
| PRIMARY ANALYSIS OF THE EORTC 1208 MINITUB TRIAL: PROSPECTIVE REGISTRY OF SENTINEL NODE (SN) POSITIVE MELANOMA PATIENTS WITH MINIMAL SN TUMOR BURDEN
Alexander van Akkooi, Australia |
Saturday, 14 September 10:15-10:25
Type: Proffered paper session Room: Salamanca Auditorium - Hall 5 Abstract number: 10760 |
| A RANDOMISED PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANDROGEN DEPRIVATION THERAPY (ADT) VS CHEMOTHERAPY (CT) IN PATIENTS WITH RECURRENT AND/OR METASTATIC, ANDROGEN RECEPTOR (AR) EXPRESSING, SALIVARY GLAND CANCERS.
Lisa Licitra, Italy. Speaker: Laura Locati, Italy |
Sunday, 15 September 11:10-11:20 Type: Proffered paper session Head and Neck Cancer Room: Valencia Auditorium - Hall 5 Abstract number: LBA36 |
| PEMBROLIZUMAB VERSUS PLACEBO AFTER A COMPLETE RESECTION OF HIGH-RISK STAGE III MELANOMA: 7-YEAR RESULTS OF THE EORTC 1325-MG/KEYNOTE-054 DOUBLE-BLIND PHASE 3 TRIAL
Alexander Eggermont, Netherlands |
Saturday, 14 September Type: Poster Display Abstract number: 1095P |
| NINTEDANIB(N) AS SWITCH MAINTENANCE TREATMENT IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) (NEMO): A DOUBLE-BLIND RANDOMIZED PHASE II TRIAL (EORTC-08112-LCG)
Omar Abdel-Rahman, Canada |
Saturday, 14 September Type: Poster Display Abstract number: 1914P |
| Gene rearrangements, actionability and access to precision medicine: Results from the ARCAGEN study
Marie Morfouace, France |
Sunday, 15 September Type: Poster Display Abstract number: 115P |
| EORTC-2129-BCG: ELACESTRANT FOR TREATING ER+/HER2- BREAST CANCER PATIENTS WITH CTDNA RELAPSE (TREAT CTDNA)
Michail Ignatiadis, Belgium |
Monday, 16 September Type: Poster Display Abstract number: 338TiP |
SESSIONS |
|
COMMON CLINICAL PROBLEMS IN NEURO-ONCOLOGY
Speaker: Martin McCabe, United Kingdom at 08:50 - 09:10 |
EDUCATIONAL SESSION Saturday, 14 September 08:30-10:00 Pamplona Auditorium - Hall 3 |
| CAN PRAGMATIC CLINICAL TRIALS AND OPTIMISATION OF TREATMENTS SUPPORT DEVELOPMENT, ACCESS AND VALUE?
Chaired by Denis Lacombe, EORTC, Belgium & Beate Wieseler, Germany |
EDUCATIONAL SESSION Saturday, 14 September 16:30-18:00 Zaragoza Auditorium - CC5 |
| RARE CANCERS Chaired by Winette van der Graaf, Netherlands & Paolo G. Casali, Italy
|
EDUCATIONAL SESSION Sunday, 15 September 10:15 - 11:45 Zaragoza Auditorium - CC5 |
YO MASTERCLASS: DESIGNING V2.0 CLINICAL TRIALS
Speaker: Saskia Litiere, EORTC, Belgium at 15:25-15:50 |
YOUNG ONCOLOGISTS SESSION Sunday, 15 September 14:45-17:45 Cartagena Auditorium - Hall 7 |
Discover more about the EORTC abstracts presented at the ESMO Congress 2024 here. For more information on the EORTC 1333/PEACE III phase III trial, read this article.
Related News
EORTC Quality of Life Group’s participation to ISOQOL 2024
10 Oct 2024
New Insights into Glioblastoma Treatment for Older Adults Patients
8 Oct 2024
TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival
24 Sep 2024
New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024
17 Sep 2024
Late Breaking Results from the EORTC 1333/PEACE III phase III trial
16 Sep 2024
Meet the new EORTC Board
9 Jul 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
17 Jun 2024
Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
24 May 2024
Clinical Trials Day 2024: a Q&A on pragmatic clinical trials
20 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
8 May 2024
